Chicago, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Preimplantation Genetic Testing market in terms of revenue was estimated to be worth $0.7 Billion in 2023 and is poised to reach $1.2 billion by 2028, growing at a CAGR of 11.4% from 2023 to 2028 according to a latest report published by MarketsandMarkets™. The growth of this market is majorly driven by the increasing number of fertility clinics worldwide, and technological advancements in genetic analysis. However, the high procedural costs associated with preimplantation genetic testing may restrain the market growth.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=605
Preimplantation Genetic Testing Market Scope:
| Report Coverage | Details |
| Market Revenue in 2023 | $0.7 Billion |
| Estimated Value by 2028 | $1.2 Billion |
| Growth Rate | Poised to grow at a CAGR of 11.4% |
| Market Size Available for | 2021–2028 |
| Forecast Period | 2023–2028 |
| Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Procedure Type, Technology, Product, Application, Type of Cycle, and End User |
| Geographies Covered | North America, Europe, Asia Pacific, and Rest of the World |
| Report Highlights | Updated financial information / product portfolio of players |
| Key Market Opportunity | Use of fertility treatment options by single parents and same-sex couples |
| Key Market Driver | Declining fertility rate |
Based on procedure type, the preimplantation genetic testing market is segmented into preimplantation genetic screening and preimplantation genetic diagnosis. The preimplantation genetic screening segment accounted for the largest share of the preimplantation genetic testing market. The large share of this segment can be attributed to factors such as greater awareness and acceptance of genetic screening techniques among prospective parents and increasing maternal age.
Based on technology, the preimplantation genetic testing market is segmented into PCR, NGS, FISH, CGH, and SNP segments. Next-generation sequencing segment is expected to dominate the preimplantation genetic testing market falling prices of sequencing, rapidly increasing penetration of NGS in diagnostics, and increasing use of these systems in fertility clinics and research institutes for preimplantation genetic diagnosis and preimplantation genetic screening.
On the basis of product and service, the preimplantation genetic diagnosis and screening market is segmented into instruments, reagents & consumables, and software & services. In 2022, the reagents and consumables segment dominated this market. The large share of this segment can be attributed to the increasing number of preimplantation genetic diagnoses and preimplantation genetic screening procedures performed worldwide.
On the basis of region, the global preimplantation genetic testing market is categorized into the North America, Europe, Asia-Pacific, and the RoW segments. North America holds the largest market share in 2022 due to the increasing government funding for genetic testing, and declining fertility rates. Other factors driving the demand for North America market include rising infertility among women in the US due to the growing prevalence of polycystic ovary syndrome (PCOS), the growing incidence of reproductive diseases such as chlamydia, and the increasing age of first-time pregnancy.
Buy a Preimplantation Genetic Testing Industry Report (245 Pages PDF with Insightful Charts, Tables, and Figures): https://www.marketsandmarkets.com/Purchase/purchase_reportNew.asp?id=605
Preimplantation Genetic Testing market major players covered in the report, such as:
- Illumina, Inc. (US)
- Thermo Fisher Scientific Inc. (US)
- Agilent Technologies, Inc. (US)
- Revvity (US)
- The Cooper Companies, Inc. (US)
- Abbott (US)
- Takara Bio Inc. (Japan)
- Qiagen (Germany)
- Vitrolife (Sweden)
- Oxford Nanopore Technologies Plc (UK)
- Oxford Gene Technology IP Limited (UK)
- Yikon Genomics (China)
- Shiva Scientific Company (India)
- Nanjing Superyears Gene Technology Co. Ltd. (China)
- Medicover Genetics (Germany)
- Medgenome (India)
- Fulgent Genetics (US)
- Invicta Genetics (Poland)
- Genea Limited (Australia)
- Scigene Corporation (US)
- Bioarray S.L. (Spain)
- Unimed Biotech (Shanghai) Co. Ltd. (China)
- Genemind Biosciences Co. Ltd. (China)
- Berry Genomics (China)
- Bangkok Genomics Innovation (Thailand)
- and Among Others
Request for FREE Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=605
This research report categorizes the Preimplantation genetic testing market into the following segments and subsegments:
Regional Split
- North America
- Europe
- Asia Pacific
- Rest of the World
Procedure Type Split
- Preimplantation Genetic Screening
- Preimplantation Genetic Diagnosis
Technology Split
- Next-Generation Sequencing
- Polymerase Chain Reaction
- Fluorescence In Situ Hybridization
- Comparative Genomic Hybridization
- Single-Nucleotide Polymorphism
Product Split
- Reagents and Consumables
- Instruments
- Software and Services
Application Split
- Aneuploidy
- Structural Chromosomal Abnormalities
- Single Gene Disorders
- X-Linked Disorders
- HLA Typing
- Gender Identification
Type of Cycle Split
- Fresh Non-Donor
- Frozen Non-Donor
- Fresh Donor
- Frozen Donor
End-user Split
- Fertility Clinics
- Hospitals
- Diagnostic Laboratories
- Other End Users
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=605
Preimplantation Genetic Testing Industry Recent Developments:
- In 2023, Thermo Fisher Scientific Inc. (US) launched two new NGS-based test kits to support preimplantation genetic testing-aneuploidy (PGT-A), commonly used in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) research.
- In 2022, The Cooper Companies, Inc. (US) released the addition of Parental QC, Genetic PN check, and Origin of Aneuploidy to PGT-A testing as PGT-Complete.
- In 2021, Vitrolife (Sweden) acquired Igenomix (Spain), a leader in reproductive genetic testing services primarily for IVF clinics.
Key Market Stakeholders:
- Senior Management
- End User
- Finance/Procurement Department
- R&D Department
Report Objectives:
- To define, describe, segment, and forecast the global preimplantation genetic testing market by procedure type, technology, product, application, type of cycle, end user, and region.
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges).
- To analyze the micro markets with respect to individual growth trends, prospects, and contributions to the overall preimplantation genetic testing market.
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players.
- To forecast the size of the market segments with respect to four regions, namely, North America, Europe, the Asia Pacific, and the Rest of the World.
- To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies.
- To benchmark players within the market using the proprietary Competitive Leadership Mapping framework, which analyzes market players on various parameters within the broad categories of business and product excellence.
Related Reports:
Digital PCR (dPCR) and Real-time PCR (qPCR) Market
Next Generation Sequencing (NGS) Market
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/preimplantation-genetic-testing-market.asp
Content Source: https://www.marketsandmarkets.com/PressReleases/preimplantation-genetic-testing.asp
